The global e-prescribing market size was estimated at USD 2.89 billion in 2022 and it is anticipated to witness a compound annual growth rate (CAGR) of 26.8% during the forecast period. Increasing adoption of electronic prescribing for controlled substances (EPSC) coupled with favorable government policies is expected to boost the market growth. At the federal level, the SUPPORT for Patients and Communities Act (H.R. 6), which Congress passed in October 2018, requires the use of electronic prescriptions for all controlled substances under Medicare Part D by January 1, 2021. Furthermore, rising awareness regarding patient safety is also anticipated to fuel market growth. During the COVID-19 pandemic, healthcare facilities were compelled to change their methods of providing their services to help curb the spread of infection among the general public and healthcare professionals. The demand for e-prescribing solutions increased, as it showed potential for improving access to prescription medicines as well as being convenient for patients. Market players also witnessed tremendous growth during the pandemic. For instance, Surescripts’ total number of e-Prescriptions exceeded 1 million prescribers in 2020.
New expansion activities, product approvals, product launches, partnerships, and acquisitions have positively impacted the e-prescribing market in recent years. For instance, in August 2021, Meddo, an India-based health startup, acquired Doxper, an e-prescription platform, which was founded in 2015 and deals in health record management and patient engagement solutions. Moreover, the market experienced a significant increase in the demand for e-prescription apps due to the growing digitalization, which in turn is fueling the market growth.
Electronic prescribing of controlled substances is now allowed in almost every state in the U.S. and Europe. The American Academy of Family Physicians (AAFP) has advocated for increased ease of EPCS implementation, and this process is improving. According to the World Health Organization, as of August 2021, around 70% of all drug use deaths are related to opioids and 30% are due to overdose. The opioid crisis in countries such as the U.S. is a major point of concern, which is expected to drive the demand for technologies such as e-prescribing. EPCS provides a secure, transparent system that makes it easier to prescribe controlled substances to patients who legitimately need them while making it more difficult to commit fraud or abuse.
The solutions segment led the market and accounted for the largest global revenue share in 2022. This large market share is attributed to their growing penetration and the high cost of the software. The segment is further bifurcated into integrated and standalone solutions. Integrated software is an assemblage of software across two or more functions intended to work on similar programs. Standalone software is meant to address only a specific operation need, such as prescribing patient medicines.
The services segment is anticipated to demonstrate the fastest growth rate of over 29% over the forecast period. E-prescribing services send electronic prescriptions from GP surgeries to pharmacies. They also offer extensive patient engagement and data management applications & analysis tools. The services segment is sub-segmented into support, implementation, training, and network. The support segment is expected to account for the largest market share. Support services can help run e-prescribing software seamlessly.
Based on delivery mode, the market is classified into web/cloud-based and on-premise. The web/cloud-based segment held the largest market share in 2022. The growth can be attributed to the low cost as compared to the on-premise systems. A cloud platform is an attractive option for independent practitioners, small clinics, or physician offices as well as community hospitals, which are not able to pay the high initial costs of the on-premise systems. Cerner, Athenahealth, Allscripts, and eClinicalWorks are some of the health IT companies that offer cloud-based solutions to users.
The on-premise segment is anticipated to witness the highest growth rate of about 26.9% during the projected period. On-premise systems are a much more reliable option for large healthcare systems and organizations, which need to store large amounts of sensitive data in secure locations. Increasing demand for data security & sharing and digitalization expenditure is expected to promote the growth of on-premise solutions during the forecast period. Epic and Cerner Corporation are two of the major players in the on-premise e-prescribing market.
Based on end-use, the market is classified into hospitals, office-based physicians, and pharmacies. The hospitals segment held the largest market share of more than 35% in 2022. The growth can be attributed to the increasing adoption of these facilities. Furthermore, the cost of installation of e-prescription solutions is less in hospitals as compared to pharmacies and office-based physicians, which also boosts the market growth.
The pharmacy segment is expected to expand at the fastest CAGR of about 27% from 2023 to 2030. The adoption of e-prescribing by pharmacies can help contribute to better health for the patient, and hence, e-prescribing has a major impact on pharmacies. E-prescribing systems can help lower operating costs and increase the efficiency of filling & refilling. Moreover, installing e-prescribing systems can improve a patient's medication adherence.
Based on the usage method, the market is classified into handheld and computer-based devices. The handheld segment held the largest market share of the global market in 2022. Handheld devices, such as PDAs, tablet computers, and smartphones, allow prescribers to access clinical decision support information such as formulary, patient medication history, and other eligibility parameters for treatment decision-making.
The computer-based devices segment is anticipated to grow at a notable rate of about 26% in the near future. E-prescribing is a computer-based electronic generation used by physicians that can help in securely transmitting the prescription to pharmacies using connectivity to a transmission network and a special software program. Upon receiving the request, the pharmacy can begin filling the medication.
Based on substances, the market is classified into controlled substances and non-controlled substances. The controlled substances segment held the largest share of the market in 2022. Any prescription drug that potentially holds some amount of drug dependence or scope of abuse is a controlled substance. EPCS technology can help curb the growing prescription drug abuse problem.
The non-controlled substances segment is anticipated to grow at the fastest rate of around 28% over the projected period. Non-controlled substances consist of medicines that are recommended to treat conditions such as diabetes, high blood pressure, and bacterial infections, as well as other over-the-counter drugs. Prescriptions for non-controlled substances are not for limitations. Non-controlled substances may be disposed of at any of the pharmacies.
Based on specialties, the market is classified into oncology, sports medicine, neurology, cardiology, and others. The sports medicine segment held the largest market share of more than 20% in 2022. Sports medicine is the field of medicine that entails preventing, diagnosing, and curing exercise-related injuries. Typical sports medicine teams include physicians, pharmacists, athletic trainers, physical therapists, and nurses.
The cardiology segment is expected to account for the fastest growth rate of around 28% during the forecast period owing to the increasing prevalence of cardiovascular diseases. With the growing cases of cardiovascular disorder and increased benefits associated with e-prescribing systems, such as hassle-free scheduling, versatile technology, and better patient & provider satisfaction, it is expected to show a major scope for growth.
The e-prescribing market is dominant in North America, which accounted for about 44% share of global revenue in 2022. The major factor contributing to the growth of this region is the high number of government initiatives and incentives in the region. Europe is the second-largest market for e-prescription software, owing to the strict regulatory policies in European countries to prevent medical errors. Furthermore, initiatives by the EU are further anticipated to lead to regional growth.
While many countries do not accept e-prescriptions from other countries, the EU issued a circular in 2019 allowing the use of an e-prescription issued by a practitioner in a different country while visiting a pharmacy in another EU country. Asia Pacific region is anticipated to demonstrate the fastest growth of around 30% during the forecast period. This growth can be attributed to an increase in the penetration of technology and rising disposable income in the region.
The market is highly competitive, with few players holding the majority of the share. With growing patient awareness and the need for minimization of medication errors, along with continued demand for cost reduction & better quality of healthcare solutions, the players are trying to develop innovative products to sustain competition. For instance, in October 2021, Allscripts Healthcare Solutions’ Veradigm partnered with CareMetx, LLC for optimizing end-to-end specialty medication access and services that streamline patient care.
Cerner and Epic hold a major market share of software solutions in e-prescription due to their vast product portfolio. As the market is still in its development stage, the growth potential is high. Furthermore, companies are also focusing on emerging countries that are expected to become major markets for the players in the coming years. Some of the key players in the global e-prescribing market include:
Cerner Corporation (Oracle)
Allscripts Healthcare, LLC
Epic Systems Corporation
NXGN Management, LLC
Practice Fusion, Inc.
Networking Technology, Inc. (RXNT)
Market size value in 2023
USD 3.66 billion
Revenue forecast in 2030
USD 19.28 billion
CAGR of 26.8% from 2023 To 2030
Base year for estimation
Actual estimates/Historical data
2017 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company share, competitive landscape, growth factors, and trends
Product, delivery mode, end-use, usage methods, substances, specialties, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; The Netherlands; Japan; China; India; Australia; Singapore; South Korea; Brazil; Argentina; Mexico; South Africa; Saudi Arabia; UAE
Key companies profiled
Cerner Corporation (Oracle); Allscripts Healthcare LLC; Epic Systems Corporation; DrFirst; Athenahealth; NXGN Management LLC; McKesson Corporation; Surescripts; Change Healthcare; Practice Fusion, Inc.; Networking Technology, Inc. (RXNT)
Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global e-prescribing market report based on product, delivery mode, end-use, usage methods, substances, specialties, and region:
Product Outlook (Revenue, USD Million, 2017 - 2030)
Delivery Mode Outlook (Revenue, USD Million, 2017 - 2030)
End-use Outlook (Revenue, USD Million, 2017 - 2030)
Usage Methods Outlook (Revenue, USD Million, 2017 - 2030)
Computer Based Devices
Substances Outlook (Revenue, USD Million, 2017 - 2030)
Specialties Outlook (Revenue, USD Million, 2017 - 2030)
Regional Outlook (Revenue, USD Million, 2017 - 2030)
Middle East & Africa
b. The global e-prescribing market size was estimated at USD 2.89 billion in 2022 and is expected to reach USD 3.66 billion in 2023.
b. The global e-prescribing market is expected to grow at a compound annual growth rate of 26.8% from 2023 to 2030 to reach USD 19.28 billion by 2030.
b. North America dominated the e-prescribing market with a share of 44.9% in 2021. This is attributable to a high number of government initiatives and incentives.
b. Some key players operating in the e-prescribing market include Cerner Corporation (Oracle), Allscripts Healthcare, LLC, Epic Systems Corporation, DrFirst, Athenahealth, NXGN Management, LLC, McKesson Corporation, Surescripts, Change Healthcare, Practice Fusion, Inc., and Networking Technology, Inc. (RXNT), among others.
b. Key factors that are driving the e-prescribing market growth include increasing pressure to minimize medical errors and Adverse Drug Events (ADEs) coupled with the need to keep a check on opioid prescriptions.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."